Arecor Therapeutics PLC - Saffron Walden, England-based biopharmaceuticals - First half of 2021 performance in line with expectations, with cash position as at June 30 of GBP22.1 million.
Now has Hikma Pharmaceuticals PLC, Eli Lilly and Par Sterile Products as part of its partner portfolio of pharmaceutical firms. Also continues to progress phase one clinical trial for ultra-concentrated rapid acting insulin, also known as AT278.
"We continue to build momentum across the business with strong progress across our in-house proprietary pipeline and further strengthening of our partner portfolio with new agreements with Hikma, Lilly and Par, further demonstrating the strength of our ArestatTM platform. With a robust financial base now in place following our successful IPO on AIM in June, we look forward to improving patient care by bringing innovative medicines to market and in doing so building further shareholder value," says Chief Executive Officer Sarah Howell.
Current stock price: 231.50 pence
Year-to-date change: down 4.3% since June 3
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Hikma Pharmaceuticals (HIK)
Arecor Therape (AREC)